Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery. Effective multiple sclerosis (MS) treatment requires thinking ...

Immunic Therapeutics was granted a patent in Europe that protects all dosing regimens of its MS therapy vidofludimus calcium ...

At the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Stephen ...

A clinical trial in China testing ICP-538, a treatment candidate for MS and other autoimmune diseases, has dosed its first healthy volunteer.

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...